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The Journal of Immunology
Mevalonate Biosynthesis Intermediates Are Key Regulators of
Innate Immunity in Bovine Endometritis
Gareth D. Healey,* Christine Collier,* Sholeem Griffin,* Hans-Joachim Schuberth,†
Olivier Sandra,‡ David G. Smith,x,{ Suman Mahan,‖ Isabelle Dieuzy-Labaye,# and
I. Martin Sheldon*
Metabolic changes can influence inflammatory responses to bacteria. To examine whether localized manipulation of the mevalonate
pathway impacts innate immunity, we exploited a uniquemucosal diseasemodel, endometritis, where inflammation is a consequence
of innate immunity. IL responses to pathogenic bacteria and LPS were modulated in bovine endometrial cell and organ cultures by
small molecules that target the mevalonate pathway. Treatment with multiple statins, bisphosphonates, squalene synthase inhib-
itors, and small interfering RNA showed that inhibition of farnesyl-diphosphate farnesyl transferase (squalene synthase), but not 3-
hydroxy-3-methylglutaryl-CoA reductase or farnesyl diphosphate synthase, reduced endometrial organ and cellular inflammatory
responses to pathogenic bacteria and LPS. Although manipulation of the mevalonate pathway reduced cellular cholesterol, impacts
on inflammation were independent of cholesterol concentration as cholesterol depletion using cyclodextrins did not alter inflam-
matory responses. Treatment with the isoprenoid mevalonate pathway-intermediates, farnesyl diphosphate and geranylgeranyl
diphosphate, also reduced endometrial cellular inflammatory responses to LPS. These data imply that manipulating the mevalonate
pathway regulates innate immunity within the endometrium, and that isoprenoids are regulatory molecules in this process, knowl-
edge that could be exploited for novel therapeutic strategies. The Journal of Immunology, 2016, 196: 823–831.
C
holesterol is the predominant sterol in vertebrates and it is
an essential component of numerous cellular processes.
Consequently, cholesterol synthesis, uptake, and efflux
are tightly regulated in cells (1). Key to the synthesis of cholesterol
is an ancient and diverse family of biological compounds called
isoprenoids, which comprises around 30,000 products of the
condensation of isopentenyl pyrophosphate and dimethylallyl di-
phosphate (2). All organisms use these isoprenoid precursors, but
they can be synthesized by two independent and nonhomologous
pathways, the methylerythritol phosphate and the mevalonate
pathways, with the mevalonate pathway dominant in eukaryotes
(Fig. 1) (1, 2). Cholesterol and lipid metabolism are essential for
normal cellular function, and disruption of mevalonate biosyn-
thesis is associated with diseases such as cancer, autoimmune
disease, heart disease, atherosclerosis, and Alzheimer’s disease
(3). Key to understanding the importance of mevalonate biosyn-
thesis in disease was seminal work by Goldstein and Brown (1) on
the rate-limiting enzyme for cholesterol biosynthesis, 3-hydroxy-
3-methylglutaryl CoA reductase (HMGCR), which paved the way
for the introduction of statin therapy.
This study used bovine endometritis as a model disease where
there is highly localized inflammation, postinfection of the en-
dometrium, initially by pathogenic Escherichia coli and then by
Trueperella pyogenes and other anaerobes in vivo (4–6). The en-
dometritis caused by pathogenic Escherichia coli is driven by
endometrial epithelial and stromal cell innate immunity, and in
particular the sensing of E. coli LPS by TLR4, which leads to
secretion of the cytokine IL-6 and the chemokine CXCL8 (6, 7).
The first objective of this study was to screen modes of action that
might modulate endometrial cell inflammatory responses to LPS
by using topical administration of small molecules to cells. Sev-
eral target pathways were identified, but the most striking finding
was that modulating the cholesterol synthesis pathway could in-
crease or decrease inflammatory responses to LPS, depending on
where in the pathway the inhibitors acted. The demand for
metabolisable energy for milk production in postpartum dairy
cows leads to significantly increased lipid mobilization, and this
lipid mobilization is often associated with metabolic and repro-
ductive disorders, including uterine disease (8). Lower serum
cholesterol concentration is also associated with uterine disease in
dairy cows (9). However, the mechanisms linking lipid meta-
bolism and uterine disease are not known.
Aiming to understand mevalonate pathway regulation of innate
immunity at the endometrial surface, to our knowledge, this is the
first comprehensive report to explore the biological link between
mevalonate biosynthesis and the occurrence of endometritis. In
doing so, this study examined how targeting mevalonate biosyn-
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thesis impacted endometrial cell inflammatory responses. We
evaluated the effect of manipulating key enzymes of the mevalonate
biosynthesis pathway on endometrial cell and ex vivo organ culture
(EVOC) responses to LPS, and live E. coli and T. pyogenes. Inhi-
bition of farnesyl-diphosphate farnesyl transferase (FDFT1; also
known as squalene synthase; Fig. 1), which leads to the accumu-
lation of isoprenoids, or treatment with isoprenoids, modulated in-
flammatory responses. Inhibiting the mevalonate pathway before
the synthesis of isoprenoids had little effect on inflammation.
Materials and Methods
Cell and organ culture
Uteri with no gross evidence of genital disease or microbial infection were
collected from postpubertal mixed-breed beef cattle (n = 144 over a 24-mo
period) within 15 min of slaughter, as part of the routine operation of a
commercial slaughterhouse. Postpartum cattle were not used because of the
ubiquitous bacterial contamination and disruption of the epithelium that is
typical of the endometrium after parturition (8, 10). The animals were 20- to
26-mo-old, reared on extensive grassland, and had never been pregnant or
inseminated. The stage of reproductive cycle was determined by examination
of ovarian morphology and vasculature, as described previously, and animals
on days 1–4 of the oestrus cycle were used because, similar to postpartum
cows, peripheral plasma ovarian hormone concentrations are basal (11). The
uteri were kept on ice for ∼1 h until further processing at the laboratory.
External surfaces were washed with 70% ethanol, and the uterine horn
opened longitudinally with sterile scissors. Because innate immune re-
sponses to LPS are the same irrespective of the horn used, one horn was used
for the isolation of purified endometrial cell populations and the contralateral
horn was used for organ culture (12).
Endometrial cells were isolated as described previously (7, 13). Epithelial
and stromal cell populations were distinguished by cell morphology, the
presence of cytokeratin and vimentin, respectively, and the absence of im-
mune cell contamination was confirmed by the absence of CD45, as de-
scribed previously (13, 14). The epithelial and stromal cells were cultured in
1 ml complete medium per well, comprising phenol red–free RPMI 1640
(Sigma-Aldrich, Dorset, U.K.) containing 10% heat-inactivated FBS (Bio-
sera, East Sussex, U.K.), and plated at 1 3 105 cells/ml in 24-well plates
(TPP, Trasadingen, Switzerland) ready for treatment. Endometrium was
collected using 8-mm diameter punch biopsy, and EVOC was performed as
described previously (15). Tissues were cultured in 24-well plates (TPP)
containing 2 ml complete medium per well, and treatments were initiated
within 4 h of slaughter. During treatment, cells or tissues were maintained in
a humidified, 5% CO2 in air atmosphere incubator at 37˚C.
Experimental design
Treatments. Cultures of E. coli (isolate MS499) (16) or T. pyogenes (isolate
MS249) (17), previously collected from the uteri of postpartum cows with
persistent uterine disease, were grown overnight in Luria-Bertani medium
(Sigma-Aldrich) and brain-heart infusion medium (Sigma-Aldrich) sup-
plemented with 5% FBS, respectively, as described previously (6, 18). The
concentration of bacteria was measured by colony count and suspended to
1 3 108 CFU/ml in sterile PBS (Life Technologies, Paisley, U.K.), fol-
lowed by centrifugation at 6000 3 g for 10 min at 4˚C. After washing,
bacteria were diluted to 1 3 103 CFU/ml (E. coli) or 1 3 108 CFU/ml
(T. pyogenes) in complete medium. Ultrapure LPS from E. coli 0111:B4
was obtained from InvivoGen (Toulouse, France) and used at 100 ng/ml,
because this concentration has previously been shown to be optimal for
stimulating IL-6 and CXCL8 responses in endometrial cells (14). Full
details of the small molecules used as a part of the inflammatory modulator
screening are provided in Supplemental Table I. The isoprenoid alcohols
farnesol and geranylgeraniol were obtained from Sigma-Aldrich.
Inflammatory response modulator screening
We selected small molecules (Supplemental Table I) and screened them for
their effect on IL-6 secretion from endometrial cells treated with LPS. In
brief, endometrial stromal cells were pretreated with control medium or
FIGURE 1. Cholesterol biosynthesis pathway. Cholesterol is the predominant sterol in vertebrates, and in eukaryotes, the mevalonate pathway is the main
synthesis pathway for cholesterol. Acetyl CoA and acetoacetyl CoA are converted via the isoprenoids (e.g., FPP and GGPP) to squalene. Three of the key
enzymes in this pathway are HMGCR, FDPS, and FDFT1. The importance of cholesterol to a variety of cellular processes means that cholesterol con-
centration within the cell is tightly regulated. Consequently, cholesterol synthesis is closely linked to cholesterol uptake via receptors such as the low-
density lipoprotein receptor (LDLR), and export from the cell via transporters such as the ATP-binding cassette transporter A1 (ABCA1).
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medium containing the small molecule of interest for 24 h, and subse-
quently challenged with control medium or 100 ng/ml LPS for a further
24 h in control medium or medium containing the small molecule. The
supernatants were collected and stored at220˚C before analysis of IL-6 by
ELISA. Cell viability was assessed by the mitochondria-dependent re-
duction of MTT to formazan, as described previously (19). The correlation
between MTT OD570 measurements and the number of live cells was
confirmed using trypan blue exclusion and counting the number of live
cells using a hemocytometer.
Inflammatory responses within bovine endometrial cells/
EVOCs
Purified endometrial epithelial (n = 9) or stromal (n = 9) cells or EVOCs
(n = 10) were pretreated with control medium or medium containing 10
mM atorvastatin to inhibit HMGCR, 10 mM squalestatin (zaragozic acid)
to inhibit FDFT1, or 25 nM dexamethasone as a positive control for 24 h.
Endometrial cells were subsequently challenged with control medium or
medium containing 100 ng/ml LPS for 24 h, whereas EVOCs were chal-
lenged with control medium, or medium containing 1 3 103 CFU/ml
E. coli or 1 3 108 CFU/ml T. pyogenes for 24 h. The supernatants were
then collected and stored at 220˚C before analysis of IL-6, CXCL8, and
IL-1b by ELISA. Cell viability was assessed by MTT as described earlier,
and EVOC tissues were weighed to enable IL concentrations to be adjusted
for tissue weight.
Inhibition of the mevalonate pathway and cholesterol
sequestration
Purified endometrial epithelial (n = 4) and stromal (n = 4) cells were
pretreated for 24 h with control medium or medium containing a range of
concentrations of atorvastatin (0.1–0 mM), etidronate (1–100 mM) to in-
hibit farnesyl diphosphate synthase (FDPS), squalestatin (0.1–10 mM), or
25 nM dexamethasone. Endometrial cells were subsequently challenged
with control medium or medium containing 100 ng/ml LPS for 24 h, in the
continued presence of the inhibitors. Supernatants were then collected and
stored at 220˚C before analysis of IL-6, and CXCL8 by ELISA. Cells
were lysed and stored in radioimmunoprecipitation assay buffer (RIPA)
buffer at 280˚C for analysis of total cell cholesterol by enzymatic assay.
For time-course experiments, purified endometrial stromal cells (n = 4)
were treated with medium containing 10 mM atorvastatin, 100 mM
etidronate, 10 mM squalestatin, or 10 mM CP-34086894 (an alternative
inhibitor of FDFT1), for 0, 6, 12, 18, 24, or 48 h. Supernatants were
discarded and cells stored in RIPA buffer at 280˚C before analysis of total
cell cholesterol by enzymatic assay.
For the membrane cholesterol sequestration experiments, purified en-
dometrial stromal cells (n = 4) were treated for 0, 1, 6, 12, or 24 h with
medium containing 1 mM methyl-b cyclodextrin, which binds to choles-
terol. Supernatants were discarded and cells lysed and stored in RIPA
buffer at 280˚C before analysis of total cell cholesterol by enzymatic
assay. To assess the impact of cholesterol reduction on inflammatory re-
sponses to LPS, we treated endometrial stromal cells (n = 4) with control
medium or medium containing 1 mM methyl-b cyclodextrin or 25 nM
dexamethasone for 24 h. Cells were then challenged with control medium
or 100 ng/ml LPS for 24 h, in the continued presence of the small mole-
cule. Supernatants were collected and stored at 220˚C before analysis of
IL-6 and CXCL8 by ELISA.
To examine the impact of small molecules on cells, we cultured en-
dometrial cells for 24 h in control medium or medium containing ator-
vastatin (0.05–10 mM), etidronate (5–200 mM), squalestatin (0.5–20 mM),
or methyl-b cyclodextrin (50–2000 mM). Cell viability was assessed by the
mitochondria-dependent reduction of MTT to formazan, as described
previously (19), and in additional independent experiments by quantifi-
cation of cellular nucleic acids using the CyQUANT Cell proliferation
Assay Kit (ThermoFisher Scientific UK), according to the manufacturer’s
instructions.
Isoprenoids and the regulation of endometrial cell
inflammatory responses to LPS
Endometrial epithelial (n = 4) and stromal (n = 4) cells were pretreated
with control medium or medium containing CP-34086894 (0.01–100 mM),
FIGURE 2. Altered cholesterol biosynthesis
modulates inflammatory responses to LPS. Endo-
metrial stromal cells were treated with small mol-
ecules from several classes of putative modulators
of inflammation for 24 h, before challenge with
control medium or 100 ng/ml LPS for 24 h (A).
Endometrial epithelial (B and C) or stromal (D and
E) cells were treated with atorvastatin (10 mM),
squalestatin (10 mM), or dexamethasone (25 nM,
Dex) for 24 h, before challenge with control me-
dium or 100 ng/ml LPS for 24 h. Supernatants were
collected and analyzed for IL-6 (A, B, and D) and
CXCL8 (C and E) by ELISA (bars), and cell via-
bility was determined by MTT assay (red squares).
Data are expressed as mean (SEM) from $4 in-
dependent experiments. Data were analyzed by
ANOVA and Dunnett’s pairwise multiple compar-
ison test; values differ from LPS treatment, *p ,
0.05.
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squalestatin (0.01–100 mM), the isoprenoids farnesol (0.01–1000 mM) or
geranylgeraniol (0.01–1000 mM), or 25 nM dexamethasone for 24 h. Cells
were subsequently challenged with 100 ng/ml LPS for 24 h in the con-
tinued presence of the small molecule, and supernatants were then col-
lected and stored at 220˚C before analysis of IL-6 and CXCL8 by ELISA.
Enzyme immune assays
Concentrations of IL-1b and IL-6 in cell and EVOC culture supernatants
were measured by ELISA, according to the manufacturer’s instructions
(Bovine IL-1b Screening Set ESS0027; ThermoFisher Scientific, Perbio
Science UK, Cramlington, U.K.; Bovine IL-6 Screening Set ESS0029;
ThermoFisher Scientific). Concentrations of CXCL8 in cell and EVOC
culture supernatants were measured by the human CXCL8/IL-8 DuoSet
ELISA according to the manufacturer’s instructions (DY208; R&D Sys-
tems Europe, Abingdon, U.K.), which has previously been validated for the
measurement of bovine CXCL8 (20) or by a recently developed bovine
CXCL8 ELISA (21). To take into account differences between the weights
of EVOC tissues, we report concentrations as picogram per milligram
tissue. The limits of detection for IL-1b, IL-6, and CXCL8 were 20.1,
35.6, and 14.3 pg/ml, respectively; the intra-assay coefficients of variance
were 4.6, 1.2, and 1.7%, and the interassay coefficients of variance were
7.7, 3.0, and 5.5%, respectively.
Cholesterol concentrations were determined using the Amplex red
cholesterol assay kit (Life Technologies). The intra-assay and interassay
coefficients of variation were,5%, and the limit of detection was 200 nM.
Gene expression analysis
Gene expression analysis was performed according to the MIQE guidelines
(22). Total RNAwas isolated from cells after lysis in RLT buffer using the
RNeasy Mini kit (Qiagen, Crawley, U.K.), and reverse transcription of
1 mg mRNA was performed in a 20-ml reaction volume using the Quanti-
Tect RT Kit (Qiagen), according to the manufacturer’s instructions.
Quantitative PCR (qPCR) for HMGCR and FDFT1 was performed using
SYBR green–based PCR with primers designed using the Eurofins MWG
Operon qPCR primer design software (https://ecom.mwgdna.com/services/
webgist/dual_probe_design?usca_pZt) and validated by BLAST analysis against
the Bos taurus (taxid: 9913) Refseq mRNA database. The HMGCR and
FDFT1 primers, and GAPDH and ACTB reference gene primers (12) were
obtained from Eurofins MWGOperon and were as follows: HMGCR forward,
59-AGGGAGAACATTGCTCGTGG-39, reverse, 59-GTAGTTGGCGAGA-
ACCGACA-39; FDFT1 forward, 59-GGGCACCCTGAGGAGTTCTAC-39,
reverse, 59-CTCCAGGGAGATCGTTGGGA-39; GAPDH forward, 59-A-
TTCCACCCACGGCAAGTTC-39, reverse, 59-TCCATCGTCCACCGCAA-
ATGCTTCT-39; ACTB forward, 59-AAGAAAAAGGGTGTAACGCAG-39,
reverse 59-TCCATCGTCCACCGCAAATGCTTCT-39. qPCR was performed
in a 25-ml reaction volume comprising 13 QuantiFast SYBR Green PCR
Master Mix (Qiagen) with primers added in nuclease-free water to a final
concentration of 0.4 mM and 2 ml cDNA. Thermal cycling parameters were:
one cycle of 95˚C for 5 min, followed by 40 cycles of 95˚C for 30 s and 60˚C
for 60 s. The expression of each gene was normalized against the geometric
mean of the two reference genes GAPDH and ACTB, which were validated as
invariant across treatment groups using standard methods (23), and the rel-
ative quantification method was used to quantify target gene mRNA within
samples as described previously (24). To generate standard curves, we re-
verse transcribed total RNA extracted from cells to cDNA. Ten-fold serial
dilutions of this reference cDNA were prepared (neat to 1 3 1025) in
nuclease-free water (Qiagen). For each sample, target and reference gene
mRNA abundance was determined from the appropriate standard curve
[quantification cycle (Cq)]. Changes in mRNA abundance between samples
were then determined from the ratio of the target gene Cq to the reference
gene Cq.
Immunoblotting
Proteins from lysed cells were normalized to 1 mg/ml using the DC Assay
(Bio-Rad) and separated (10 mg per lane) using 10% (v/v) SDS-PAGE,
with m.w. markers run in parallel lanes (Bio-Rad). After electrophoresis,
proteins were transferred to a polyvinylidene difluoride membrane (Bio-
Rad); nonspecific sites were blocked using a solution of 5% (w/v) BSA
FIGURE 3. Modulating cholesterol homeostasis
impacts the inflammatory response of endometrium
to bacteria. Endometrial EVOCs were treated with
control medium or medium containing atorvastatin
(10 mM), squalestatin (10 mM), or dexamethasone
(25 nM, Dex) for 24 h and then challenged with
control medium or 1 3 103 CFU/ml live E. coli or
1 3 108 CFU/ml live T. pyogenes for 24 h. Su-
pernatants were collected for analysis of IL-6 (A
and B), CXCL8 (C and D), and IL-1b (E and F) by
ELISA. Data are presented as mean (SEM) from 10
independent experiments. Data were analyzed by
ANOVA and Dunnett’s pairwise multiple compar-
ison t test. Values differ from E. coli or T. pyogenes
treatment, *p , 0.05.
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(Sigma-Aldrich) in TBS overnight at 4˚C with gentle agitation. Membranes
were probed with Abs targeting FDFT1 (NBP1-54855; Novus Biologicals,
Cambridge, U.K.), and HMGCR (ab98018; Abcam, Cambridge, U.K.), using
Abs selected based on recognition of immunoreactive proteins of appropriate
m.w. Primary Abs were used at 1:500 dilutions in 5% (w/v) BSA in TBS for
2 h with gentle agitation. After incubation, membranes were washed three
times for 5 min in TBS and 0.1% Tween 20 (pH 7.6). Membranes were then
incubated in secondary HRP-conjugated Ab (Cell Signaling Technology,
Danvers, MA) in 5% (w/v) BSA in TBS for 1.5 h and washed three times for
5 min in TBS and 0.1% Tween 20 (pH 7.6). Steady-state levels of immu-
noreactive proteins were visualized using ECL (Western C; Bio-Rad). Protein
loading was evaluated and normalized by examining b-actin protein levels
using a b-actin Ab (Abcam). The average peak densities of unsaturated bands
were analyzed using Quantity-one software (Bio-Rad).
siRNA
Primary endometrial stromal cells (n = 4) were transfected with Lipofectamine
RNAiMAX Reagent (Invitrogen) and small interfering RNA (siRNA;
designed using Dharmacon siDESIGN Center; Thermo Scientific) target-
ing HMGCR and FDFT1. siRNA duplex sequences were siHMG: sense 59-
CAGCAUGGAUAUUGAACAAUU-39, antisense 59-UUGUUCAAU-
AUCCAUGCUGUU-39; siFDFT1: sense 59-GCGAGAAGGGAGA-
GAGUUUUU-39, antisense 59-AAACUCUCUCCCUUCUCGCUU-39. In brief,
RNAiMAX-RNAi duplex complexes were formed by adding 50 pmol siRNA to
500 ml Opti-MEM I Reduced Serum Media (without antibiotics; Invitrogen) in
each well of a six-well plate (Helena Bioscience). For controls, 50 pmol
ONTARGETplus Nontargeting siRNA #1 (Dharmacon) was used instead
of the targeted siRNA. Then 7.5 ml RNAiMAX was added to each well
containing the diluted RNAi molecules and left for 20 min at room
temperature. Exponentially growing cells were then seeded in 2.5 ml
complete medium without antibiotics per well to give ∼50% confluence
(5 3 105 cells/well). All transfections were carried out in duplicate.
Cells were challenged with 100 ng/ml LPS, 24 h after the addition of the
siRNA, and changes in mRNA and protein expression were assessed
48 h after transfection.
Statistical analyses
Statistical analyses were performed using IBM SPSS Statistics 20 with the
animal as the experimental unit. Initially the data were tested for homo-
geneity, and log or square root transformed if appropriate. Data were an-
alyzed by ANOVA and Dunnett’s pairwise multiple comparison t test, or by
Student t test. Data are presented as SEM, a p value ,0.05 was considered
statistically significant, and n represents the number of animals.
Results
Cholesterol biosynthesis and LPS-mediated inflammation
We initially explored putative modes of action that might modulate
inflammatory responses to LPS. Bovine endometrial stromal cell
secretion of IL-6 in response to 24-h treatment with 100 ng/ml LPS
is a well-established model of endometritis (7, 14). Primary
stromal cells isolated from the uteri of 46 animals were used to
screen 49 small molecules (Supplemental Table I). At least four
animals were used to test each molecule, and cell viability was
determined by MTT assay. Cellular responsiveness to LPS was
confirmed in each experiment (control versus LPS 70.6 6 10.9
versus 1567.9 6 405.9 pg/ml IL-6, p , 0.001). In addition,
dexamethasone was used as a positive control because it has a
well-established anti-inflammatory effect, which was confirmed in
the present screening system (LPS versus Dex + LPS 1567.9 6
405.9 versus 304.9 6 62.4 pg/ml IL-6, p , 0.001). Molecules of
interest were defined by an inflammatory response .1 SD from
the reference response to LPS. Based on the IL-6 response and cell
viability data presented in Supplemental Table I, JAK-STAT sig-
naling, nuclear receptor signaling, chemokine receptor signaling,
and cholesterol biosynthesis were identified as potential targets for
therapeutic intervention aimed at reducing cellular inflammatory
responses to LPS. Of particular interest were molecules targeting
cholesterol or cholesterol biosynthesis (Fig. 1), where there was a
differential cellular response to several modulators of the pathway
(Fig. 2A). After exposure to LPS, endometrial stromal cells pre-
treated with squalestatin produced less IL-6 compared with LPS-
treated cells, whereas cells treated with atorvastatin increased IL-6
production (Fig. 2A). These data imply that disruption of lipid
metabolism and the mevalonate pathway may influence endome-
trial innate immune inflammatory responses to LPS.
A B C D
HGFE
I J K L
FIGURE 4. Endometrial cell inflammatory responses to LPS are attenuated by blocking FDFT1, but not FDPS or HMGCR. Endometrial epithelial (A, B,
E, F, I, and J) and stromal (C, D, G, H, K, and L) cells were treated with control medium of medium containing atorvastatin (0.1–10 mM), etidronate (1–100
mM), squalestatin (0.1–10 mM), or 25 nM dexamethasone for 24 h. Cells were subsequently challenged with control medium or 100 ng/ml LPS for a further
24 h. Supernatants were collected for analysis of IL-6 (A, C, E, G, I, and K) and CXCL8 (B, D, F, H, J, and L) by ELISA (bars), and cells were lysed and
stored in RIPA buffer for analysis of cholesterol (CHO) concentration by enzymatic assay (red squares). Data are presented as mean (SEM) from four
independent experiments. Data were analyzed by ANOVA and Dunnett’s pairwise multiple comparison t test; values differ from LPS (0 + LPS), *p , 0.05,
**p , 0.01, ***p , 0.001; or values differ from control (0), *p , 0.05, **p , 0.01. ND, not detected.
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Cholesterol biosynthesis and inflammatory responses within
the bovine endometrium
The differential effect of inhibiting cholesterol biosynthesis on
LPS-mediated inflammation was further explored using purified
endometrial cell populations and intact endometrial organ cultures.
Epithelial cells secreted more IL-6 (control versus LPS 28.26 19.1
versus 246.9 6 30.8 pg/ml IL-6, p , 0.05) and more CXCL8
(control versus LPS 3.1 6 3.1 versus 125.7 6 6.4 pg/ml CXCL8,
p , 0.05) in response to challenge with 100 ng/ml LPS for 24 h,
as expected. However, pretreatment of epithelial cells with ator-
vastatin for 24 h increased IL-6 but not CXCL8 secretion in re-
sponse to LPS challenge (Fig. 2B, 2C), whereas pretreatment with
squalestatin or the positive control dexamethasone reduced the secre-
tion of IL-6 (p, 0.05) and CXCL8 (p, 0.05). Stromal cells secreted
more IL-6 (control versus LPS 32.9 6 15.4 versus 1765.8 6 190.4
pg/ml IL-6, p, 0.05) and more CXCL8 (control versus LPS 11.66
6.6 versus 88.1 6 12.5 pg/ml CXCL8, p , 0.05) in response to
challenge with 100 ng/ml LPS for 24 h. Pretreatment of stromal
cells with atorvastatin for 24 h had no significant effect on IL-6 or
CXCL8 secretion, but pretreatment with squalestatin or dexameth-
asone for 24 h reduced the secretion of IL-6 in response to LPS
challenge (p, 0.05), and dexamethasone also reduced the secretion
of CXCL8 (p , 0.05; Fig. 2D, 2E).
To further explore the effect of differential targeting of choles-
terol biosynthesis on inflammatory responses, we used EVOCs of
endometrium and live pathogenic bacteria isolated from clinical
cases of endometrial disease (Fig. 3) (12, 15, 25). As expected,
EVOCs challenged with 1 3 103 CFU/ml live E. coli accumulated
more IL-6 (control versus E. coli 11.6 6 3.9 versus 172.9 6 10.8
pg IL-6 per mg tissue, p , 0.05), CXCL8 (control versus E. coli
0.46 0.2 versus 70.36 19.9 pg/mg CXCL8, p, 0.05), and IL-1b
(control versus E. coli 3.3 6 1.0 versus 9.3 6 3.0 pg/mg IL-1b,
p , 0.05). However, pretreatment of EVOCs for 24 h with squa-
lestatin reduced the accumulation of IL-6 (p , 0.05; Fig. 3A),
whereas squalestatin and dexamethasone reduced the accumu-
lation of CXCL8 (p , 0.05; Fig. 3C), and pretreatment with
dexamethasone also reduced the accumulation of IL-1b (p ,
0.05; Fig. 3E). Atorvastatin had no significant effect on inflam-
matory responses to live E. coli. Challenge of EVOCs with 1 3 108
CFU/ml live T. pyogenes stimulated the production of more IL-6
(control versus T. pyogenes 11.6 6 3.9 versus 234.3 6 57.0 pg/mg
IL-6, p , 0.05), CXCL8 (control versus T. pyogenes 0.4 6 0.2
versus 39.36 8.3 pg/mg IL-6, p, 0.05), and IL-1b (control versus
T. pyogenes 3.3 6 1.0 versus 20.9 6 6.1 pg/mg IL-1b, p , 0.05).
Pretreating EVOCs with atorvastatin for 24 h before challenge had
no significant effect on subsequent IL responses to live T. pyogenes.
However, pretreatment with squalestatin reduced the accumulation
of IL-6 (p, 0.05; Fig. 3B), CXCL8 (p, 0.05; Fig. 3D), and IL-1b
(p , 0.05; Fig. 3F). Taken together, these data indicate that squa-
lestatin was most effective at limiting inflammatory responses to
live bacteria or LPS in the endometrium, with a similar level of
effect to the positive control dexamethasone.
Cellular cholesterol concentration and inflammatory responses
to LPS
Based on the contrasting responses to atorvastatin and squalestatin,
which act at different points in the mevalonate pathway, we rea-
soned that metabolites of mevalonate were likely responsible for
the differing impact on the cytokine and chemokine responses.
Therefore, to elucidate which molecules might alter inflammatory
responses, we inhibited the mevalonate pathway in endometrial
cells at three biologically relevant points: 1) HMGCR, 2) FDPS,
and 3) FDFT1 (Fig. 1), using atorvastatin, etidronate, and squa-
lestatin, respectively (Fig. 4). The effectiveness of the mevalonate
pathway inhibitors used was first examined by measuring endo-
metrial cell cholesterol content. Treatment for 24 h with the higher
concentrations of atorvastatin (Fig. 4A, 4B) or squalestatin
(Fig. 4I, 4J) reduced total epithelial cell cholesterol in the pres-
ence of LPS (p , 0.05), whereas the FDPS inhibitor, etidronate,
had no significant effect on cholesterol concentrations (Fig. 4E,
4F). Stromal cell cholesterol was reduced by 100 mM etidronate in
the presence of LPS (p , 0.05; Fig. 4G, 4H), and by 1 or 10 mM
squalestatin in the presence or absence of LPS (p , 0.05; Fig. 4K,
4L), although not by atorvastatin (Fig. 4C, 4D). As in our previous
experiments, endometrial cells secreted IL-6 and CXCL8 in re-
sponse to challenge with 100 ng/ml LPS (p , 0.001; Fig. 4), and
pretreatment with atorvastatin for 24 h before LPS challenge had
FIGURE 5. Reduced total cell cholesterol is not responsible for the
modulation of LPS-mediated inflammation. Endometrial stromal cells
were treated with medium containing methyl-b cyclodextrin (1 mM) for 0,
1, 6, 12, or 24 h, and cells were lysed and stored in RIPA buffer for
analysis of total cell cholesterol concentration by enzymatic assay (A).
Endometrial stromal cells were treated with control medium or medium
containing methyl-b cyclodextrin (MBCD; 1 mM) or dexamethasone
(Dex; 25 nM) for 24 h before challenge with control medium or 100 ng/ml
LPS for a further 24 h. Supernatants were collected for analysis of IL-6 (B)
and CXCL8 (C) by ELISA. Data are presented as mean (SEM) from four
independent experiments. Data were analyzed by ANOVA and Dunnett’s
pairwise multiple comparison t test; values differ from 0 h, or LPS treat-
ment, *p , 0.05, **p , 0.01, ***p , 0.001.
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no effect on IL-6 or CXCL8 secretion by epithelial (Fig. 4A, 4B)
or stromal cells (Fig. 4C, 4D). Similarly, pretreatment for 24 h
with etidronate did not impact IL-6 or CXCL8 secretion from
epithelial (Fig. 4E, 4F) or stromal cells (Fig. 4G, 4H). However,
pretreatment with squalestatin for 24 h reduced CXCL8 responses
to LPS challenge in epithelial cells (p , 0.05; Fig. 4J), and IL-6
(p , 0.01; Fig. 4K) and CXCL8 (p , 0.05; Fig. 4L) responses to
LPS challenge in stromal cells. These data imply that total cellular
cholesterol concentrations may influence cytokine and chemokine
responses to LPS.
To further investigate the potential role of cholesterol, we treated
endometrial stromal cells with atorvastatin, etidronate, or squa-
lestatin for 48 h and measured total cell cholesterol concentrations
at several time points (Supplemental Fig. 1). Squalestatin signif-
icantly reduced total cell cholesterol by 18 h with a 62% reduction
by 24 h (p, 0.05; Supplemental Fig. 1C). In contrast, atorvastatin
only reduced cholesterol concentrations after 48 h (p , 0.05;
Supplemental Fig. 1A), and etidronate only tended to reduce
cholesterol by 48 h (p = 0.07; Supplemental Fig. 1B). To ascertain
whether the cellular cholesterol reduction was specific for squa-
lestatin, we treated stromal cells with an alternative FDFT1 in-
hibitor, CP34086894, which also significantly reduced cholesterol
concentrations by 18 h, with a 58% reduction by 24 h (p , 0.05;
Supplemental Fig. 1D). To determine whether reduced cell cho-
lesterol may be causally associated with reduced inflammatory
responses to LPS, we used methyl-b cyclodextrin, which se-
questers cholesterol molecules from the cell membrane, to rapidly
reduce stromal cell cholesterol concentrations by a mechanism
that does not involve inhibiting the mevalonate pathway (26).
Endometrial stromal cells treated with 1 mM methyl-b cyclo-
dextrin had significantly lower cholesterol after 1-h treatment, and
the concentration was 87% lower by 24 h (p , 0.001; Fig. 5A).
However, pretreatment with methyl-b cyclodextrin for 24 h had
no effect on IL-6 (Fig. 5B) or CXCL8 (Fig. 5C) secretion after
challenge with LPS. To address whether cellular cholesterol re-
duction might affect cell health, we assessed cell viability using
the MTT assay and the number of cells using the CyQUANT assay
(Supplemental Fig. 2). Treatment of endometrial stromal cells
with atorvastatin (0.05–10 mM; Supplemental Fig. 2A, 2B),
etidronate (5–200 mM; Supplemental Fig. 2C, 2D), squalestatin
(0.5–20 mM; Supplemental Fig. 2E, 2F), or methyl-b cyclodextrin
(50–2000 mM; Supplemental Fig. 2G, 2H) for 24 h had no sig-
nificant detrimental effect on cell viability or cell survival. Taken
together these data indicate that changes in cellular cholesterol
concentrations alone did not account for how manipulation of the
mevalonate pathway modulated inflammatory responses to LPS.
Isoprenoids and inflammation in the bovine endometrium
In the absence of a direct effect of reduced cellular cholesterol
concentrations on inflammation, the role of mevalonate metab-
olites was investigated. Extended dose range experiments deter-
mined that the inhibition of FDFT1 by either CP34086894
(Fig. 6A–D) or squalestatin (Fig. 6E–H) potently reduced endo-
metrial epithelial (p , 0.05; Fig. 6A, 6B, 6E, 6F) and stromal
(p , 0.05; Fig. 6C, 6D, 6G, 6H) cell IL-6 and CXCL8 responses
to LPS. The data presented in Figs. 4 and 6 indicate that reduced
cytokine and chemokine secretion is particularly associated with
FIGURE 6. Endometrial cell inflammatory responses to LPS are attenuated in a dose-dependent manner by inhibition of FDFT1. Endometrial epithelial
(A, B, E, and F) and stromal (C, D, G, and H) cells were treated with control medium or medium containing CP-34086894 [(A–D) 0.01–100 mM],
squalestatin [(E–H) 0.01–100 mM], or dexamethasone (Dex; 25 nM) for 24 h. After treatment, cells were challenged with control medium or 100 ng/ml LPS
for 24 h. Supernatants were collected for analysis of IL-6 (A, E, C, and G) and CXCL8 (B, F, D, and H) by ELISA. Data are presented as mean (SEM) from
four independent experiments. Data were analyzed by ANOVA and Dunnett’s pairwise multiple comparison t test; values differ from LPS treatment, *p ,
0.05, **p , 0.01, ***p , 0.001.
FIGURE 7. RNA interference of HMGCR or FDFT1 modulates endo-
metrial stromal cell innate immune responses to LPS. Endometrial stromal
cells were transfected with scrambled siRNA (siScram) or siRNA targeting
HMGCR (siHMG) or FDFT1 (siFDFT1) for 48 h. After transfection, cells
were challenged with control medium or 100 ng/ml LPS for 24 h. Su-
pernatants were collected for analysis of IL-6 (A) and CXCL8 (B) by
ELISA. Data are presented as mean (SEM) from four independent ex-
periments. Data were analyzed by ANOVA and Dunnett’s pairwise mul-
tiple comparison t test; values differ from LPS treatment, *p , 0.05,
**p , 0.01, ***p , 0.001.
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inhibition of the mevalonate pathway at the level of FDFT1, rather
than HMGCR or FDPS. To provide evidence that the effects of
inhibition of the mevalonate pathway were not due to off-target
effects of the inhibitors used earlier, we treated endometrial
stromal cells with siRNA targeting HMGCR (siHMG) and FDFT1
(siFDFT1). The effectiveness of siRNA treatment was confirmed
using qPCR and Western blot (Supplemental Fig. 3). Treatment of
endometrial stromal cells with siHMG and siFDFT1 reduced
HMGCR and FDFT1 mRNA by 52 and 42%, respectively
(Supplemental Fig. 3A, 3B), and protein abundance was also re-
duced (Supplemental Fig. 3C, 3D). Pretreatment of endometrial
stromal cells with siFDFT1 reduced IL-6 (p , 0.05; Fig. 7A) and
CXCL8 (p , 0.05; Fig. 7B) secretion after challenge with LPS.
Conversely, pretreatment with siHMG increased IL-6 (p , 0.001;
Fig. 7A) and CXCL8 (p , 0.01; Fig. 7B) secretion after challenge
with LPS.
Because inhibition of FDFT1 will increase the concentration
of the isoprenoids farnesyl diphosphate (FPP) and geranylgeranyl
diphosphate (GGPP), they might be important regulators of innate
immunity. To examine this concept, we treated endometrial cells
with farnesol and geranylgeraniol isoprenoid alcohols, which are
converted intracellularly to their respective pathway intermediate
diphosphates, FPP and GGPP (27, 28). Pretreatment of endome-
trial cells for 24 h with farnesol (Fig. 8A–D) or geranylgeraniol
(Fig. 8E–H) reduced IL-6 and CXCL8 responses to subsequent
challenge with LPS. In particular, the pretreatment of endometrial
epithelial (p , 0.1; Fig. 8A) or stromal (p , 0.05; Fig. 8C) cells
with farnesol for 24 h significantly reduced the accumulation of
IL-6 in response to challenge with LPS (p, 0.05), and pretreatment
of stromal cells with geranylgeraniol for 24 h significantly reduced
the accumulation of CXCL8 (p , 0.01; Fig. 8H). Together, the use
of inhibitors, siRNA, and agonists supports the concept that innate
immunity is modulated by isoprenoids.
Discussion
Evidence is emerging that integration of innate immunity, lipid
metabolism, and cholesterol biosynthesis impact the development
of uterine disease (8, 9). This study used primary isolated bovine
endometrial cells and EVOCs as well-characterized models of
endometritis (7, 15), to explore cellular pathways that modulate
inflammatory responses within the endometrial tissue. Of partic-
ular interest were differential inflammatory responses after tar-
geting of enzymes within the mevalonate pathway. Inhibition of
the rate-limiting enzyme HMGCR by statins had little effect on
cellular inflammatory responses, but inhibition of the enzyme
FDFT1 was as effective as using the standard anti-inflammatory,
dexamethasone. There was evidence that the reduced inflamma-
tion was not a consequence of lower cellular cholesterol, but
rather mediated by isoprenoids.
Inhibition of FDFT1 by squalestatin or CP34086894 was
equally effective at reducing the inflammatory response to bacteria
in organ cultures, or to LPS in epithelial or stromal cells. In ad-
dition, siRNA targeting FDFT1 reduced LPS-mediated IL-6 and
CXCL8 secretion by endometrial cells. The more rapid and effi-
cient reduction in cholesterol within cells treated with FDFT1
inhibitors, compared with atorvastatin or etidronate, implied that
cellular cholesterol may impact innate immune responsiveness to
LPS. However, a similar reduction of cholesterol using methyl-b
cyclodextrin had no effect on LPS-mediated IL-6 secretion, suggesting
that cellular cholesterol was not the determining factor for modulating
innate immunity. Indeed, cholesterol reduction per se is also not the
main mechanism of statin-driven immune modulation, which occurs
primarily via disrupted intracellular signaling and trafficking brought
about by a reduction of intracellular cholesterol intermediates (29).
In this study, inhibition of HMGCR either had no effect or in-
creased LPS-mediated endometrial innate immune responses. The
implication in this study is that molecules downstream from
mevalonate are capable of regulating endometrial innate immune
responses to LPS. At high concentrations, statins reduce the pro-
duction of isoprenoids, including FPP and GGPP, in various cell
types through depletion of isoprenoid precursors within the
mevalonate pathway (29–33). The isoprenoids FPP and GGPP are
essential for the posttranslational modification, membrane at-
tachment, and biological activity of Ras-family G proteins and
Rho GTPases, respectively (34, 35). Therefore, their depletion
within the cell affects a wide range of cellular pathways, as indeed
does their excessive accumulation (36, 37). In humans, the effect
of manipulating isoprenoid availability on LPS responsiveness is
exemplified by reduced TLR4 expression on monocytes isolated
from patients treated with statins for 4 wk. Reduced TLR4 ex-
pression and LPS-mediated inflammatory responses are mediated
via inhibition of protein geranylgeranylation and farnesylation,
further demonstrating the importance of the interaction between
cholesterol biosynthesis and innate immunity (33).
Inhibition of FDFT1, by inhibitors or siRNA, increases intra-
cellular concentrations of FPP and GGPP (36, 37). Furthermore,
FIGURE 8. Endometrial cell inflammatory responses to LPS are attenuated in a dose-dependent manner by the addition of isoprenoids. Endometrial
epithelial (A, B, E, and F) and stromal (C, D, G, and H) cells were treated with control medium or medium containing farnesol [(A–D) 0.01–1000 mM],
geranylgeraniol [(E–H) 0.01–1000 mM], or dexamethasone (Dex; 25 nM) for 24 h. After treatment, cells were challenged with control medium or 100 ng/ml
LPS for 24 h. Supernatants were collected for analysis of IL-6 (A, E, C, and G) and CXCL8 (B, F, D, and H) by ELISA. Data are presented as mean (SEM)
from four independent experiments. Data were analyzed by ANOVA and Dunnett’s pairwise multiple comparison t test; values differ from LPS treatment,
*p , 0.05, **p , 0.01, ***p , 0.001. ND, not detected.
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the isoprenoid alcohols, farnesol and geranylgeraniol, both of
which are converted to their respective pathway intermediate di-
phosphates, FPP and GGPP (27, 28), attenuated endometrial cell IL-
6 and CXCL8 responses to LPS in this study. The anti-inflammatory
effect of isoprenoids has previously been demonstrated in a mouse
model of mevalonate kinase deficiency, a rare disorder characterized
by recurrent inflammatory episodes. Systemic inflammatory re-
sponses, induced by the administration of muramyldipeptide and the
aminobisphosphonate alendronate, were inhibited by the addition of
exogenous isoprenoids demonstrating an immune-regulatory func-
tion (38). Furthermore, the inflammatory phenotype of mevalonate
kinase deficiency in humans is specifically driven by a lack of
mevalonate-derived isoprenoids (39). The implication is that iso-
prenoids are involved in the regulation of inflammation, and our data
demonstrate that FPP and GGPP regulate inflammation within the
endometrium. The basis for this regulation remains unclear, and
elucidation of the molecular mechanisms involved requires further
work, which will form the foundation of future studies.
In summary, we show that manipulating the mevalonate
pathway modulates innate immunity in endometrial cells and
tissue. Surprisingly, inhibition of FDFT1 (squalene synthase)
reduced inflammatory responses to bacteria or LPS in contrast with
modulating the rate-limiting enzyme, HMGCR, with statins, which
had no beneficial effect. These findings are important because they
uncover a role for FDFT1 and geranyl and farnesyl isoprenoids in
mucosal immunity. Furthermore, these findings could be translated
to use topical administration of FDFT1 inhibitors into the uterus
to limit the severity of bacterial endometritis.
Acknowledgments
We thank James Cronin and Steve Jeremiah for assistance with ELISA.
Disclosures
The authors have no financial conflicts of interest.
References
1. Goldstein, J. L., and M. S. Brown. 1990. Regulation of the mevalonate pathway.
Nature 343: 425–430.
2. Lombard, J., and D. Moreira. 2011. Origins and early evolution of the meval-
onate pathway of isoprenoid biosynthesis in the three domains of life. Mol. Biol.
Evol. 28: 87–99.
3. Thurnher, M., G. Gruenbacher, and O. Nussbaumer. 2013. Regulation of mevalonate
metabolism in cancer and immune cells. Biochim. Biophys. Acta 1831: 1009–1015.
4. Sheldon, I. M., D. E. Noakes, A. N. Rycroft, D. U. Pfeiffer, and H. Dobson. 2002.
Influence of uterine bacterial contamination after parturition on ovarian dominant
follicle selection and follicle growth and function in cattle. Reproduction 123: 837–845.
5. Bonnett, B. N., S. W. Martin, V. P. Gannon, R. B. Miller, and W. G. Etherington.
1991. Endometrial biopsy in Holstein-Friesian dairy cows. III. Bacteriological
analysis and correlations with histological findings. Can. J. Vet. Res. 55: 168–173.
6. Sheldon, I. M., A. N. Rycroft, B. Dogan, M. Craven, J. J. Bromfield,
A. Chandler, M. H. Roberts, S. B. Price, R. O. Gilbert, and K. W. Simpson. 2010.
Specific strains of Escherichia coli are pathogenic for the endometrium of cattle
and cause pelvic inflammatory disease in cattle and mice. PLoS One 5: e9192.
7. Cronin, J. G., M. L. Turner, L. Goetze, C. E. Bryant, and I. M. Sheldon. 2012.
Toll-like receptor 4 and MYD88-dependent signaling mechanisms of the innate
immune system are essential for the response to lipopolysaccharide by epithelial
and stromal cells of the bovine endometrium. Biol. Reprod. 86: 51–60.
8. Wathes, D. C., Z. Cheng, W. Chowdhury, M. A. Fenwick, R. Fitzpatrick,
D. G. Morris, J. Patton, and J. J. Murphy. 2009. Negative energy balance alters
global gene expression and immune responses in the uterus of postpartum dairy
cows. Physiol. Genomics 39: 1–13.
9. Sepu´lveda-Varas, P., D. M. Weary, M. Noro, and M. A. von Keyserlingk. 2015.
Transition diseases in grazing dairy cows are related to serum cholesterol and
other analytes. PLoS One 10: e0122317.
10. Herath, S., S. T. Lilly, N. R. Santos, R. O. Gilbert, L. Goetze, C. E. Bryant,
J. O. White, J. Cronin, and I. M. Sheldon. 2009. Expression of genes associated
with immunity in the endometrium of cattle with disparate postpartum uterine
disease and fertility. Reprod. Biol. Endocrinol. 7: 55–68.
11. Ireland, J. J., P. B. Coulson, and R. L. Murphree. 1979. Follicular development
during four stages of the estrous cycle of beef cattle. J. Anim. Sci. 49: 1261–1269.
12. Saut, J. P., G. D. Healey, A. M. Borges, and I. M. Sheldon. 2014. Ovarian ste-
roids do not affect bovine endometrial cytokine or chemokine responses to
Escherichia coli or LPS in vitro. Reproduction 148: 593–606.
13. Herath, S., D. P. Fischer, D. Werling, E. J. Williams, S. T. Lilly, H. Dobson,
C. E. Bryant, and I. M. Sheldon. 2006. Expression and function of Toll-like
receptor 4 in the endometrial cells of the uterus. Endocrinology 147: 562–570.
14. Turner, M. L., J. G. Cronin, G. D. Healey, and I. M. Sheldon. 2014. Epithelial
and stromal cells of bovine endometrium have roles in innate immunity and
initiate inflammatory responses to bacterial lipopeptides in vitro via Toll-like
receptors TLR2, TLR1, and TLR6. Endocrinology 155: 1453–1465.
15. Borges, A. M., G. D. Healey, and I. M. Sheldon. 2012. Explants of intact en-
dometrium to model bovine innate immunity and inflammation ex vivo. Am. J.
Reprod. Immunol. 67: 526–539.
16. Goldstone, R. J., R. Talbot, H. J. Schuberth, O. Sandra, I. M. Sheldon, and
D. G. Smith. 2014. Draft Genome Sequence of Escherichia coli MS499, Isolated
from the Infected Uterus of a Postpartum Cow with Metritis. Genome Announc.
2: e00217-14.
17. Goldstone, R. J., M. Amos, R. Talbot, H. J. Schuberth, O. Sandra, I. M. Sheldon,
and D. G. Smith. 2014. Draft Genome Sequence of Trueperella pyogenes, Iso-
lated from the Infected Uterus of a Postpartum Cow with Metritis. Genome
Announc. 2: e00194-14.
18. Amos, M. R., G. D. Healey, R. J. Goldstone, S. M. Mahan, A. D€uvel, H. J. Schuberth,
O. Sandra, P. Zieger, I. Dieuzy-Labaye, D. G. E. Smith, and I. M. Sheldon. 2014.
Differential endometrial cell sensitivity to a cholesterol-dependent cytolysin links
Trueperella pyogenes to uterine disease in cattle. Biol. Reprod. 90: 54–67.
19. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival:
application to proliferation and cytotoxicity assays. J. Immunol. Methods 65: 55–
63.
20. Rinaldi, M., F. Ceciliani, C. Lecchi, P. Moroni, and D. D. Bannerman. 2008.
Differential effects of alpha1-acid glycoprotein on bovine neutrophil respiratory
burst activity and IL-8 production. Vet. Immunol. Immunopathol. 126: 199–210.
21. Cronin, J. G., R. Hodges, S. Pedersen, and I. M. Sheldon. 2015. Enzyme linked
immunosorbent assay for quantification of bovine interleukin-8 to study infection
and immunity in the female genital tract. Am. J. Reprod. Immunol. 73: 372–382.
22. Bustin, S. A., V. Benes, J. A. Garson, J. Hellemans, J. Huggett, M. Kubista,
R. Mueller, T. Nolan, M. W. Pfaffl, G. L. Shipley, et al. 2009. The MIQE
guidelines: minimum information for publication of quantitative real-time PCR
experiments. Clin. Chem. 55: 611–622.
23. Vandesompele, J., K. De Preter, F. Pattyn, B. Poppe, N. Van Roy, A. De Paepe,
and F. Speleman, 2002. Accurate normalization of real-time quantitative RT-
PCR data by geometric averaging of multiple internal control genes. Genome
Biol. 3: RESEARCH0034.
24. Nolan, T., R. E. Hands, and S. A. Bustin. 2006. Quantification of mRNA using
real-time RT-PCR. Nat. Protoc. 1: 1559–1582.
25. Sheldon, I. M., J. Cronin, L. Goetze, G. Donofrio, and H. J. Schuberth. 2009.
Defining postpartum uterine disease and the mechanisms of infection and im-
munity in the female reproductive tract in cattle. Biol. Reprod. 81: 1025–1032.
26. Zidovetzki, R., and I. Levitan. 2007. Use of cyclodextrins to manipulate plasma
membrane cholesterol content: evidence, misconceptions and control strategies.
Biochim. Biophys. Acta 1768: 1311–1324.
27. Crick, D. C., D. A. Andres, and C. J. Waechter. 1997. Novel salvage pathway
utilizing farnesol and geranylgeraniol for protein isoprenylation. Biochem.
Biophys. Res. Commun. 237: 483–487.
28. Thai, L., J. S. Rush, J. E. Maul, T. Devarenne, D. L. Rodgers, J. Chappell, and
C. J. Waechter. 1999. Farnesol is utilized for isoprenoid biosynthesis in plant
cells via farnesyl pyrophosphate formed by successive monophosphorylation
reactions. Proc. Natl. Acad. Sci. USA 96: 13080–13085.
29. Wang, C. Y., P. Y. Liu, and J. K. Liao. 2008. Pleiotropic effects of statin therapy:
molecular mechanisms and clinical results. Trends Mol. Med. 14: 37–44.
30. Sinensky, M., L. A. Beck, S. Leonard, and R. Evans. 1990. Differential inhibi-
tory effects of lovastatin on protein isoprenylation and sterol synthesis. J. Biol.
Chem. 265: 19937–19941.
31. Takemoto, M., and J. K. Liao. 2001. Pleiotropic effects of 3-hydroxy-3-methylglutaryl
coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 21: 1712–1719.
32. Petras, S. F., S. Lindsey, and H. J. Harwood, Jr. 1999. HMG-CoA reductase
regulation: use of structurally diverse first half-reaction squalene synthetase in-
hibitors to characterize the site of mevalonate-derived nonsterol regulator pro-
duction in cultured IM-9 cells. J. Lipid Res. 40: 24–38.
33. Methe, H., J. O. Kim, S. Kofler, M. Nabauer, and M. Weis. 2005. Statins de-
crease Toll-like receptor 4 expression and downstream signaling in human CD14
+ monocytes. Arterioscler. Thromb. Vasc. Biol. 25: 1439–1445.
34. Mital, S., X. Zhang, G. Zhao, R. D. Bernstein, C. J. Smith, D. L. Fulton,
W. C. Sessa, J. K. Liao, and T. H. Hintze. 2000. Simvastatin upregulates coro-
nary vascular endothelial nitric oxide production in conscious dogs. Am. J.
Physiol. Heart Circ. Physiol. 279: H2649–H2657.
35. Yoshida, Y., M. Kawata, M. Katayama, H. Horiuchi, Y. Kita, and Y. Takai. 1991.
A geranylgeranyltransferase for rhoA p21 distinct from the farnesyltransferase
for ras p21S. Biochem. Biophys. Res. Commun. 175: 720–728.
36. Keller, R. K. 1996. Squalene synthase inhibition alters metabolism of nonsterols
in rat liver. Biochim. Biophys. Acta 1303: 169–179.
37. Keller, R. K., D. A. Mitchell, C. C. Goulah, and S. J. Fliesler. 2013. Hepatic
isoprenoid metabolism in a rat model of Smith-Lemli-Opitz Syndrome. Lipids
48: 219–229.
38. Marcuzzi, A., A. Pontillo, L. De Leo, A. Tommasini, G. Decorti, T. Not, and
A. Ventura. 2008. Natural isoprenoids are able to reduce inflammation in a
mouse model of mevalonate kinase deficiency. Pediatr. Res. 64: 177–182.
39. Frenkel, J., G. T. Rijkers, S. H. Mandey, S. W. Buurman, S. M. Houten,
R. J. Wanders, H. R. Waterham, and W. Kuis. 2002. Lack of isoprenoid products
raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and
periodic fever syndrome. Arthritis Rheum. 46: 2794–2803.
The Journal of Immunology 831
 at Sw
ansea U
niv/W
ales on January 22, 2016
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
Supplemental Table I 
Small molecules screened 
 
Name Formula MW Mode of action Supplier IL-6  ± SEM (pg/ml) 
Cell Viability 
± SEM  
(% control) 
PF-03052334-02 Not available 224.9 HMG CoA reductase (antagonist) Pfizer 
1801.2 ± 
599.1  148.3 ± 15.5 
PF-00261809-02 Not available 212.1 HMG CoA reductase (antagonist) Pfizer 732.2 ± 190.8 71.9 ± 31.5 
PF-02887172-02 Not available 220.4 HMG CoA reductase (antagonist) Pfizer 691.2 ± 209.2 88.8 ± 29.5 
PF-03591518-02 Not available 188.13 HMG CoA reductase (antagonist) Pfizer 675.0 ± 186.1 83.5 ± 27.6 
PF-03491165-00 Not available 214.2 HMG CoA reductase (antagonist) Pfizer 827.1 ± 239.4 83.9 ± 29.0 
PF-03201237-02 Not available 177.8 HMG CoA reductase (antagonist) Pfizer 791.1 ± 224.7 85.3 ± 31.0 
Atorvastatin C33H35FN2O5 558.64 HMG CoA reductase (antagonist) Pfizer 
3112.9 ± 
875.1 101.1 ± 9.4 
Squalestatin C35H46O14 690.73 FDFT1 (antagonist) Glaxo SmithKline 408.7 ± 86.4 88.0 ± 31.2 
CP-340868-94 C32H35ClN2O4S 579.14 FDFT1 (antagonist) Pfizer 287.9 ± 43.0 222.0 ± 7.1 
TO901317 C17H12NSO3F9 481.3 LXR (oxysterol receptor) (agonist) Sigma-Aldrich 828.4 ±89.9 225.9 ± 16.4 
Alpha 
cyclodextrin C36H60O30 972.84 Cholesterol sequester Sigma-Aldrich 930.6 ± 256.5 100.8 ± 25.7 
Beta cyclodextrin C42H70O35 1134.98 Cholesterol sequester Sigma-Aldrich 952.9 ± 288.4 105.8 ± 5.7 
Methyl-beta 
cyclodextrin C56H98O35 1310 Cholesterol sequester Sigma-Aldrich 
1009.4 ± 
263.0 110.9 ± 12.0 
Gamma 
cyclodextrin C48H80O40 1297.12 Cholesterol sequester Sigma-Aldrich 
1140.3 ± 
330.0 101.4 ± 7.4 
Resolvin D1 C22H32O5 376.5 Resolvin D1 receptor (antagonist) Cayman Chemical 784.0 ± 44.1 81.9 ± 3.4 
Lipoxin A4 C20H32O5 352.5 Lipoxin A4 receptor (antagonist) Cayman Chemical 804.2 ± 44.7 90.6 ± 22.2 
CP-481715 C26H31FN4O4 482.54 Chemokine receptor 1 (antagonist) Pfizer 
437.5824 ± 
185.2 162.6 ± 42.4 
865569 Not available - Chemokine receptor 1 (antagonist) Pfizer 666.9 ± 98.3 177.9 ± 39.3 
04136309-00 Not available - Chemokine receptor 2 (antagonist) Pfizer 507.0 ± 197.4 188.1 ± 34.6 
04973563-00 Not available - Chemokine receptor 5 (antagonist) Pfizer 607.5 ± 94.2 186.9 ± 36.1 
00227153-00 Not available - Chemokine receptor 5 (antagonist) Pfizer 732.6 ± 105.7 178.8 ± 29.2 
230988-A Not available - Chemokine receptor 2/5 (antagonist) Pfizer 786.0 ± 87.6 135.9 ± 22.7 
04178903-00 Not available - Chemokine receptor 2/5 (antagonist) Pfizer 604.2 ± 154.2 180.7 ± 31.1 
04254196-18 Not available - Chemokine receptor 2/5 (antagonist) Pfizer 875.0 ± 117.8 158.3 ± 35.0 
Dexamethasone C22H29FO5 392.46 Glucocorticoid receptor (agonist) Sigma-Aldrich 304.9 ± 49.2 141.9 ± 12.6 
Oestradiol C18D3H21O2 272.38 Oestrogen receptor (agonist) Sigma-Aldrich 
901.547 ± 
107.4 107.1 ± 8.7 
Progesterone C21H30O2 314.46 Progesterone receptor (agonist) Sigma-Aldrich 868.4 ± 201.5 92.0 ± 4.9 
ERB-041 C15H10FNO3 271.24 Oestrogen receptor  beta (agonist) Pfizer 930.2 ± 134.2 190.1 ± 9.5 
2,3-Bis(4-
hydroxyphenyl)pr
opionitrile 
C15H13NO2 239.27 Oestrogen receptor  beta (agonist) Sigma-Aldrich 899.3 ± 149.6 231.4 ± 20.1 
1,3,5-Tris(4-
hydroxypheyl)-4-
propyl-1H-
pyrazole 
C24H22N2O3 386.44 Oestrogen receptor  alpha (agonist) Sigma-Aldrich 1054.2 ± 87.8 178.7 ± 19.1 
1,3-Bis(4-
hydroxyphenyl)-
4-methyl-5-[4-(2-
piperidinylethoxy)
phenol]-1H-
pyrazole 
dihydrochloride 
hydrate 
C29H31N3O3 542.50 Oestrogen receptor  alpha (antagonist) Sigma-Aldrich 995.1 ± 142.9 204.9 ± 17.1 
Mifepristone (RU-
486) C29H35NO2 429.59 
Progesterone and 
glucocorticoid 
receptor (antagonist) 
Sigma-Aldrich 944.0 ± 174.6 296.1 ± 38.1 
PF-02413873-00 C18H21N3O3S 359.44 Progesterone receptor (antagonist) Pfizer 821.1 ± 135.7 296.7 ± 54.3 
PF-03491390 C26H27F4N3O7 569.50 Pan-caspase (antagonist) Pfizer 856.2 ± 97.3 188.9 ± 34.3 
CE-224535 C22H29ClN4O6 480.94 P2X7 receptor (antagonist) Pfizer 
726.5482 ± 
157.3 
179.9 ± 38.6 
 
PF184 C32H32ClFN6O4 619.09 IkappaB kinase complex (antagonist) Tocris Bioscience 769.0 ± 195.4 220.4 ± 11.0 
IRAK4 Not available - IRAK4 inhibitor Pfizer 108.1 ± 17.3 152.1 ± 32.4
IKK Not available - IKK inhibitor Pfizer 163.6 ± 10.8 96.9 ± 24.3
MEK Not available - MEK inhibitor Pfizer 155.4 ± 36.2 123.0 ± 18.1 
P38 733836 Not available - p38 inhibitor Pfizer 215.9 ± 43.5 97.9 ± 8.7 
P38 709733 Not available - p38 inhibitor Pfizer 301.8 ± 80.1 132.2 ± 3.0 
Tpl2 199727 Not available - Tpl2 kinase inhibitor Pfizer 245.7 ± 57.2 115.9 ± 7.9 
Tpl2 397103 Not available - Tpl2 kinase inhibitor Pfizer 206.8 ± 79.4 149.3 ± 21.1 
JAK Not available - JAK inhibitor Pfizer 222.8 ± 69.0 115.8 ± 19.8 
STATVI C16H15NO7S 365.36 STAT3 inhibitor - 242.6 ± 178.7 73.7 ± 12.4 
STATTIC C8H5NO4S 211.2 STAT3 inhibitor Merck Millipore 353.4 ± 184.3 66.9 ± 6.2 
ULHA Not available - - - 145.7 ± 32.3 102.8 ± 1.1 
HHA Not available - - - 256.3 ± 38.9 111.9 ± 4.6 
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Supplemental figure 2
CyQuantMTT
Cellular cholestreol reduction did not affect cell health. Endometrial
stromal cells were treated with Atorvastatin (0.05 - 10 M), Etidronate (5 - 200
M), Squalestatin 0.5 - 20 M) or Methyl- Cyclodextrin (50 - 2000 M) for 24
h. Supernatants were removed and cell viability assessed by MTT assay as a
percent of control (A, C, E,  G). At the end of the assay the number of cells
were measured as a percent of control using the CyQUANT assay (B, D, F,
H). Data are presented as mean (SEM) from four indepenednt experiments.
Data were analysed by  ANOVA and Dunnett's pairwise multiple comparison
t-test; values do not differ from control, P > 0.05.
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Supplemental figure 3
Treatment of endometrial stromal cells with siRNA attenuated the expression of target
RNA and protein. Endometrial stromal cells were transfected with control scrambled siRNA
(siScram) or siRNA targeting HMGCR (siHMG) or FDFT1 (siFDFT1). Supernatants were
removed and cells lysed and stored in RLT buffer at -80°C for analysis of HMGCR and
FDFT1 by quantitative PCR (A, B), or RIPA buffer at -80°C for analysis of HMGCR and
FDFT1 by western blot (C,  D). Data presented as mean (SEM) from three independent
experiments. Data were analysed by ANOVA and Dunnett's pairwise multiple comparison
t-test; values differ from control, * P < 0.05, ** P < 0.01.
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